Viking Therapeutics Starts Phase 3 Trial Program for Oral VK2735 in Obesity
The company announced initiation of its oral VK2735 Phase 3 clinical program in patients with obesity.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.